

LA POLIOMIELITIS HA SIDO ERRADICADA DE LAS AMÉRICAS

El último caso con poliovirus salvaje fue detectado el 5 de septiembre de 1991, en Perú



Vigilancia de la Poliomielitis en las Américas

Cuadro No.1
Análisis de las muestras de heces de casos
Últimas 52 semanas (2011/30 - 2012/29)

| Lab. | País | Total ¹ | SIN RESULTADOS | | | | AISLAMIENTO DE VIRUS | | | | | | | |
|--------------|------------------|--------------------|----------------|-----------|------------|-----------|--------------------------|-------------|-------------------|-------------|------------|--------------------|----------|----------|
| | | | Aún no en lab. | ≤14 días | 15-21 días | >21 días | % Aislamiento | Negativo | Otros Enterovirus | Otros Virus | Poliovirus | | | |
| | | | | | | | | | | Pendiente | Vacunal | Derivado de vacuna | Salvaje | |
| CAR | DOM | 24 | 0 | 0 | 0 | 0 | 16.7 | 20 | 3 | 0 | 0 | 1 | 0 | 0 |
| | HND | 70 | 4 | 2 | 1 | 2 | 13.1 | 53 | 3 | 5 | 0 | 0 | 0 | 0 |
| | HTI | 4 | 4 | 0 | 0 | 0 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | JAM | 3 | 0 | 0 | 0 | 2 | 0.0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | NIC | 16 | 3 | 0 | 0 | 0 | 15.4 | 11 | 1 | 0 | 1 | 0 | 0 | 0 |
| | PAN | 5 | 0 | 0 | 0 | 0 | 20.0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 |
| | SLV | 1 | 0 | 0 | 0 | 0 | 0.0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| CDC | GTM | 57 | 0 | 0 | 0 | 13 | 18.2 | 36 | 8 | 0 | 0 | 0 | 0 | 0 |
| | HND | 1 | 1 | 0 | 0 | 0 | -- | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | PRY | 13 | 2 | 0 | 0 | 0 | 18.2 | 9 | 2 | 0 | 0 | 0 | 0 | 0 |
| | SLV | 42 | 7 | 0 | 0 | 3 | 6.3 | 30 | 0 | 2 | 0 | 0 | 0 | 0 |
| FIO | BRA | 294 | 46 | 0 | 0 | 6 | 8.3 | 222 | 9 | 0 | 0 | 11 | 0 | 0 |
| | PER | 93 | 8 | 0 | 0 | 0 | 10.6 | 76 | 8 | 0 | 0 | 1 | 0 | 0 |
| IEC | BRA | 51 | 3 | 0 | 0 | 2 | 2.2 | 45 | 1 | 0 | 0 | 0 | 0 | 0 |
| INDRE | MEX ² | 143 | 32 | 55 | 40 | 0 | 7.4 | 88 | 5 | 0 | 1 | 1 | 0 | 0 |
| INS | COL | 143 | 0 | 0 | 0 | 0 | 5.6 | 135 | 7 | 0 | 0 | 1 | 0 | 0 |
| | CRI | 24 | 0 | 0 | 0 | 1 | 0.0 | 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| | ECU | 37 | 1 | 0 | 0 | 11 | 4.0 | 24 | 1 | 0 | 0 | 0 | 0 | 0 |
| IPK | CUB | 17 | 6 | 0 | 0 | 0 | 0.0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 |
| ISP | CHL | 81 | 0 | 0 | 0 | 0 | 0.0 | 81 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAL | ARG ³ | 127 | 0 | 0 | 0 | 18 | 13.8 | 111 | 7 | 0 | 0 | 8 | 0 | 0 |
| | BOL | 33 | 1 | 0 | 0 | 0 | 15.6 | 27 | 5 | 0 | 0 | 0 | 0 | 0 |
| | URY | 2 | 0 | 0 | 0 | 0 | 0.0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | | 1281 | 118 | 57 | 42 | 80 | 10.0 ⁴ | 1010 | 61 | 7 | 2 | 23 | 0 | 0 |

¹ Cada muestra se refiere a un individuo

Case samples only

² Datos de México sólo del 2012 (al 18 julio de 2012)

³ Datos en revisión en el sistema ISIS.

⁴ Total excluye a México

Cuadro No.2
Poliovirus con diferenciación intratípica (ITD)
Últimas 52 semanas (2011/30 - 2012/29)

| Lab. | País | Casos AFP con ITD | | | Poliovirus pendiente de ITD | | | | | | | | | | | | | |
|--------------|------|-------------------|----------|--------------|-----------------------------|----|----|-----|---------------------|----|----|-----|---------------------|----|----|-----|-------|---|
| | | ≤ 7 días | Total | % | Aún no en el lab. | | | | En lab. < de 7 días | | | | En lab. > de 7 días | | | | Total | |
| | | | | | P1 | P2 | P3 | MIX | P1 | P2 | P3 | MIX | P1 | P2 | P3 | MIX | | |
| MAL | ARG | 2 | 7 | 28.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total | | 2 | 7 | 28.57 | | | | | | | | | | | | | | |

Muestras de casos solamente



Cuadro No.1
Casos de parálisis flácida aguda bajo investigación
Según semana de inicio de parálisis

| Sub Región | País | Total 2011 | Acum. 2012 | Semana | | | | | | | | | | | |
|--------------|--------|------------|------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|----------|----------|----------|----------|--|
| | | | | 1-8 | 9-16 | 17-21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | |
| AND | BOL | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| | COL | 0 | 8 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 3 | 0 | 0 | |
| | ECU | 0 | 17 | 6 | 8 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | PER | 0 | 25 | 3 | 4 | 8 | 2 | 2 | 3 | 3 | 0 | 0 | 0 | 0 | |
| | VEN | 0 | 6 | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| BRA | BRA | 0 | 51 | 7 | 25 | 10 | 2 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | |
| CAP | CRI | 3 | 5 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
| | GTM | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | HND | 0 | 8 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 2 | 1 | 0 | 0 | |
| | NIC | 0 | 14 | 2 | 5 | 2 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | |
| | PAN | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CAR | SLV | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | CAR | 0 | 10 | 5 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| LAC | CUB | 0 | 6 | 2 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | DOM | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | HTI | 0 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| MEX | MEX*** | 0 | 172 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| NOA | CAN | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | |
| | USA | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| SOC | ARG | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | |
| | CHL | 0 | 29 | 2 | 7 | 5 | 3 | 2 | 5 | 1 | 1 | 2 | 0 | 2 | |
| | PRY | 0 | 8 | 3 | 0 | 1 | 0 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | |
| | URY | 0 | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | |
| Total | | 6 | 373 | 32 | 59 | 41 | 13 | 13 | 18 | 11 | 6 | 7 | 0 | 2 | |

***Al 18 de julio del 2012

Cuadro No.2
Casos de PFA notificados, tasa por 100,000 <15 años,
% de casos investigados dentro 48 horas, % con 1 muestra adecuada y % de unidades notificando semanalmente

| Sub Región | País | Polio 2012 | | Casos PFA e Indicadores de últimas 52 semanas (2011/30 - 2012/29) | | | | % Unid. notificando | Polio 2011 | | Casos PFA e Indicadores 2011 (2011/01 - 2011/52) | | | | % Unid. notificando |
|----------------|------|------------|------------|---|-------------|--------------------|-------------|---------------------|------------|------------|--|-------------|--------------------|-------------|---------------------|
| | | Confirmado | Compatible | Casos | Tasa | % Invest. <48 hrs. | %1 Muestra+ | | Confirmado | Compatible | Casos | Tasa | % Invest. <48 hrs. | %1 Muestra+ | |
| AND | BOL | 0 | 0 | 33 | 0.91 | 91 | 82 | ... | 0 | 0 | 41 | 1.13 | 90 | 85 | ... |
| | COL | 0 | 0 | 151 | 1.15 | 46 | 81 | ... | 0 | 0 | 157 | 1.20 | 62 | 82 | 91 |
| | ECU | 0 | 0 | 43 | 0.95 | 35 | 63 | 61 | 0 | 0 | 39 | 0.88 | 31 | 72 | 86 |
| | PER | 0 | 0 | 112 | 1.34 | 88 | 66 | 0 | 0 | 0 | 132 | 1.58 | 89 | 77 | 100 |
| | VEN | 0 | 0 | 61 | 0.71 | 87 | 75 | 0 | 0 | 0 | 71 | 0.83 | 72 | 85 | ... |
| BRA | BRA | 0 | 0 | 380 | 0.77 | 98 | 77 | 94 | 0 | 1 | 561 | 1.13 | 97 | 76 | 95 |
| CAP | CRI | 0 | 0 | 27 | 2.36 | 52 | 78 | ... | 0 | 0 | 38 | 3.15 | 39 | 82 | ... |
| | GTM | 0 | 0 | 57 | 0.77 | 54 | 79 | ... | 0 | 0 | 60 | 0.78 | 97 | 78 | ... |
| | HND | 0 | 0 | 71 | 2.10 | 100 | 89 | 177 | 0 | 0 | 63 | 1.86 | 100 | 92 | 92 |
| | NIC | 0 | 0 | 29 | 1.44 | 86 | 86 | ... | 0 | 0 | 28 | 1.39 | 96 | 89 | 100 |
| | PAN | 0 | 0 | 7 | 0.70 | 86 | 71 | 79 | 0 | 0 | 9 | 0.90 | ... | ... | 87 |
| CAR | SLV | 0 | 0 | 44 | 1.80 | 52 | 82 | ... | 0 | 0 | 59 | 2.44 | 51 | 78 | ... |
| | CAR | 0 | 0 | 25 | 0.45 | 92 | 4 | 67 | 0 | 0 | 25 | 0.59 | 76 | 16 | 66 |
| LAC | CUB | 0 | 0 | 18 | 0.89 | 100 | 94 | 100 | 0 | 0 | 32 | 1.58 | 100 | 94 | 100 |
| | DOM | 0 | 0 | 24 | 0.73 | 46 | 92 | 56 | 0 | 0 | 42 | 1.27 | 88 | 84 | 100 |
| | HTI | 0 | 0 | 5 | 0.10 | 40 | 80 | 47 | 0 | 0 | 10 | 0.17 | ... | 90 | ... |
| MEX | MEX | 0 | 0 | ... | ... | ... | ... | ... | 0 | 0 | 496 | 1.57 | 95 | 56 | 100 |
| NOA | CAN | 0 | 0 | 20 | 0.35 | NR | 30 | NR | 0 | 0 | 35 | 0.62 | NR | 34 | NR |
| | USA | 0 | 0 | NR | NR | NR | NR | NR | 0 | 0 | NR | NR | NR | NR | NR |
| SOC | ARG | 0 | 0 | 132 | 1.26 | 45 | 81 | 121 | 0 | 0 | 172 | 1.68 | 31 | 83 | 107 |
| | CHL | 0 | 0 | 91 | 2.36 | 93 | 76 | 99 | 0 | 0 | 89 | 2.30 | 96 | 85 | 100 |
| | PRY | 0 | 0 | 20 | 0.95 | 60 | 75 | ... | 0 | 0 | 18 | 0.90 | 56 | 67 | 93 |
| | URY | 0 | 0 | 4 | 0.52 | 0 | 50 | 3 | 0 | 0 | 9 | 1.17 | 11 | 67 | 4 |
| Total § | | 0 | 0 | 1354 | 0.80 | 74 | 77 | - | - | 1 | 2186 | 1.30 | 91 | 77 | 95 |

+ Tomado dentro de los primeros 14 días del inicio de parálisis
§ Excluyendo EUA

... - Sin datos
NR - No reportando

CAR incluye informes de todos sus países miembros